Xtant Medical (XTNT) to Release Quarterly Earnings on Thursday

Xtant Medical (NYSEAMERICAN:XTNT) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Xtant Medical to post earnings of ($0.0049) per share and revenue of $30.75 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Xtant Medical Stock Performance

Shares of Xtant Medical stock opened at $0.57 on Thursday. The business has a 50-day moving average price of $0.66 and a two-hundred day moving average price of $0.68. Xtant Medical has a 1-year low of $0.34 and a 1-year high of $0.95. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35. The company has a market cap of $80.47 million, a P/E ratio of 57.54 and a beta of -0.04.

Analyst Upgrades and Downgrades

Separately, BTIG Research lowered their target price on Xtant Medical from $2.00 to $1.50 and set a “buy” rating for the company in a report on Tuesday, November 11th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, Xtant Medical presently has an average rating of “Buy” and a consensus target price of $1.50.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in XTNT. Jane Street Group LLC bought a new position in shares of Xtant Medical during the second quarter valued at about $26,000. Mink Brook Asset Management LLC increased its stake in Xtant Medical by 125.8% in the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares during the last quarter. Wiregrass Investment Management LLC purchased a new stake in Xtant Medical in the 4th quarter valued at about $81,000. Vanguard Group Inc. lifted its position in shares of Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after buying an additional 104,159 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Xtant Medical by 28.8% in the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after buying an additional 205,945 shares during the last quarter. 69.33% of the stock is owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.